REW 40 Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Immunomedics, Inc. (NQ: IMMU)
3.140 USD  -0.010 (-0.32%)
Official Closing Price  /  Updated: 5:20 PM EDT, May 22, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 3.140
Bid (Size) 3.140 (8800)
Ask (Size) 3.150 (24200)
Prev. Close 3.150
Today's Range 3.070 - 3.270
52wk Range 2.110 - 3.760
Shares Outstanding 82,720,783
Dividend Yield N/A
Top News
More News
Traders Get Bullish on Shares of Immunomedics, Shares Up 8.1% (IMMU)
May 13, 2013
from Comtex SmarTrend® News Briefs
Immunomedics, Inc. (IMMU) Swings to Q3 Profit
May 08, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8319141 for the full story. Read More
from StreetInsider.com News Articles

More News
Read More
Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments
May 08, 2013
from GlobeNewswire News Releases
Immunomedics Reports Three New Patent Wins
May 07, 2013
category Benzinga , News , IMMU
from Latest Articles from Benzinga.com
Immunomedics Announces Three New Patent Awards
May 07, 2013
from GlobeNewswire News Releases
Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2013 Financial Results
April 25, 2013
from GlobeNewswire News Releases
Immunomedics (IMMU) Updates on Preclinical Data for T-cell Redirecting Agent Development
April 10, 2013
from StreetInsider.com News Articles
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors
April 10, 2013
category Benzinga , News , IMMU
from Latest Articles from Benzinga.com
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors
April 10, 2013
from GlobeNewswire News Releases
Immunomedics Announces First Results of Labetuzumab-SN-38 in Colorectal Cancer Study
April 09, 2013
category Benzinga , News , FDA , and 1 more.
from Latest Articles from Benzinga.com
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here